In the future, we will evaluate the efficacy of PgP as a therapeutic gene delivery carrier in preclinical animal models of SCI, traumatic brain injury, stroke, and other neurodegenerative diseases such as Alzheimer’s Disease, Parkinson’s diseases, Huntington’s Diseases, and Amyotrophic Lateral Sclerosis. This evidence concerns the gene PGP and Parkinson disease.